文献速递乳腺癌放疗放疗物理与技术

两种人工智能模型自动生成乳腺癌计划生成的临床评估

Clinical evaluation of two AI models for automated breast cancer plan generation.
PubMed 文献 · Radiat Oncol · 2022-02-05

本研究对20例左侧淋巴结阴性乳腺癌患者(处方剂量40.05 Gy,切线束调强放疗),比较了两种AI模型(自研U-net与商用cARF)生成的可执行计划与手动计划的临床可接受性。U-net和cARF模型计划的PTV平均/最大剂量及心脏/肺平均剂量略高于手动计划,但90-95%的AI计划被四位放疗科医生评为临床可接受,手动计划为90%;计划准备时间U-net与手动相当,cARF较长。

要点

  • U-net模型PTV平均剂量中位差异0.37 Gy、最大剂量0.47 Gy,心脏平均剂量略高0.01 Gy。
  • cARF模型PTV平均剂量高0.30 Gy、最大剂量高0.39 Gy,心脏平均剂量高0.02 Gy、肺平均剂量高0.04 Gy。
  • 90-95%的AI计划被四位放疗科医生评为临床可接受,手动计划为90%。

核心结论

  • 两种AI模型均能以省时、需极少用户交互的方式为乳腺癌患者生成可执行计划。
  • 尽管AI计划整体剂量略高,放疗科医生认为90-95%的AI计划临床可接受。

研究设计与样本

  • 对20例左侧淋巴结阴性乳腺癌患者(处方剂量40.05 Gy,切线束调强放疗),评估两种基于模型的治疗计划与对应手动计划。
  • 两种模型分别为自研U-net模型和商用上下文图谱回归森林模型(cARF)。
  • 由四位放疗科医生对盲法计划进行临床可接受性评估并按偏好排序,同时基于剂量体积直方图参数、临床评估标准和准备时间与手动计划比较。

主要发现

  • U-net模型导致PTV平均剂量和最大剂量中位差异分别为0.37 Gy和0.47 Gy,心脏平均剂量(MHD)略高0.01 Gy。
  • cARF模型导致PTV平均剂量和最大剂量分别高0.30 Gy和0.39 Gy,MHD略高0.02 Gy,肺平均剂量(MLD)高0.04 Gy。
  • 两种AI计划的最大MHD/MLD差异均≤0.5 Gy。
  • 90-95%的AI计划被认为临床可接受,手动计划为90%。
  • 放疗科医生之间的偏好存在差异。

关键数值与推荐

  • 处方剂量40.05 Gy,采用切线束调强放疗。
  • 临床可接受性由四位放疗科医生基于盲法计划评估。
  • 剂量比较基于剂量体积直方图参数、临床评估标准和准备时间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Artificial intelligence (AI) shows great potential to streamline the treatment planning process. However, its clinical adoption is slow due to the limited number of clinical evaluation studies and because often, the translation of the predicted dose distribution to a deliverable plan is lacking. This study evaluates two different, deliverable AI plans in terms of their clinical acceptability based on quantitative parameters and qualitative evaluation by four radiation oncologists. METHODS: For 20 left-sided node-negative breast cancer patients, treated with a prescribed dose of 40.05 Gy, using tangential beam intensity modulated radiotherapy, two model-based treatment plans were evaluated against the corresponding manual plan. The two models used were an in-house developed U-net model and a vendor-developed contextual atlas regression forest model (cARF). Radiation oncologists evaluated the clinical acceptability of each blinded plan and ranked plans according to preference. Furthermore, a comparison with the manual plan was made based on dose volume histogram parameters, clinical evaluation criteria and preparation time. RESULTS: The U-net model resulted in a higher average and maximum dose to the PTV (median difference 0.37 Gy and 0.47 Gy respectively) and a slightly higher mean heart dose (MHD) (0.01 Gy). The cARF model led to higher average and maximum doses to the PTV (0.30 and 0.39 Gy respectively) and a slightly higher MHD (0.02 Gy) and mean lung dose (MLD, 0.04 Gy). The maximum MHD/MLD difference was ≤ 0.5 Gy for both AI plans. Regardless of these dose differences, 90-95% of the AI plans were considered clinically acceptable versus 90% of the manual plans. Preferences varied between the radiation oncologists. Plan preparation time was comparable between the U-net model and the manual plan (287 s vs 253 s) while the cARF model took longer (471 s). When only considering user interaction, plan generation time was 121 s for the cARF model and 137 s for the U-net model. CONCLUSIONS: Two AI models were used to generate deliverable plans for breast cancer patients, in a time-efficient manner, requiring minimal user interaction. Although the AI plans resulted in slightly higher doses overall, radiation oncologists considered 90-95% of the AI plans clinically acceptable.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kneepkens E, Bakx N, van der Sangen M, et al. Clinical evaluation of two AI models for automated breast cancer plan generation. Radiat Oncol. 2022. PMID: 35123517. doi:10.1186/s13014-022-01993-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。